Quality of life three years after diagnosis of localised prostate cancer: Population based cohort study

BMJ (Online)

Volumn 340, Issue 7739, 2010, Pages 195-

  Smith, David P ^a   King, Madeleine T ^b   Egger, Sam ^a   Berry, Martin P ^c   Stricker, Phillip D ^d   Cozzi, Paul ^e   Ward, Jeanette ^f   O'Connell, Dianne L ^a   Armstrong, Bruce K ^g  

^a Cancer Council   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c LIVERPOOL HOSPITAL   (Australia)

^d ST VINCENT'S CLINIC   (Australia)

^e ST GEORGE HOSPITAL   (Australia)

^f UNIVERSITY OF OTTAWA   (Canada)

^g UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

SILDENAFIL; TADALAFIL; VARDENAFIL;

ADULT; AGED; ALTERNATIVE MEDICINE; ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; ARTICLE; AUSTRALIA; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER REGISTRY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEALTH; HUMAN; INTESTINE FUNCTION; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; MENTAL HEALTH; ORCHIECTOMY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RISK ASSESSMENT; SEXUAL FUNCTION; SHORT FORM 12; TREATMENT OUTCOME; URINARY DYSFUNCTION;

EID: 76249087422     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b4817     Document Type: Article

References (39)

1. TraceyEA,BakerD, ChenW, StavrouE,BishopJ. Cancer in New South Wales: incidence, mortality and prevalence, 2005. Cancer Institute New South Wales, 2007.
2. Ries LAG,MelbertD, KrapchoM, MariottoA, MillerBA, Feuer EJ, et al. SEER cancer statistics review, 1975-2004. National Cancer Institute, 2007.
3. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann InternMed 2008;148:435-48.
4. Smith DP, Supramaniam R, King MT, Ward J, Berry M, Armstrong BK. Age, health, and education determine supportive care needs ofmen younger than 70 years with prostate cancer. J Clin Oncol 2007;25:2560-6.
5. Australian Cancer Network Working Party, National Health and Medical Research Council (NHMRC). Clinical practice guidelines: evidence-based information and recommendations of localised prostate cancer. AusInfo Government Info Bookshops, Commonwealth of Australia, 2002.
6. Australian Institute of Health and Welfare (AIHW) 2007. ACIM (Australian Cancer Incidence and Mortality) Books. AIHW, 2007.
7. Potosky AL, Harlan LC, Stanford JL, Gilliland FD, Hamilton AS, Albertsen PC, et al. Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 1999;91:1719-24.
8. Legler J, Potosky AL, Gilliland FD, Eley JW, Stanford JL. Validation study of retrospective recall of disease-targeted function: results from the prostate cancer outcomes study. Med Care 2000;38:847-57.
9. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66.
10. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al for the measurement committee of the American Urological Association. The American urological association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549-57.
11. Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol 2005;173:1701-5.
12. Ware JE Jr, Kosinsky M, Keller SD. SF-36 physical and mental health summary scales: a user'smanual. New England Medical Center, 1994.
13. Australian Bureau of Statistics. National health survey: SF-36 population norms, Australia. ABS, 1997.
14. Litwin MS. RAND 12-item health survey v2 (SF-12 v2) and UCLA prostate cancer index short form health-related quality of life scoring instructions. UCLA Departments of Urology and Health Services, 2002.
15. Schwartz CE, Sprangers MA. Adaptation to changing health. response shift in quality-of-life research. American Psychological Association, 2000.
16. Zeliadt SB, Etzioni R, Ramsey SD, Penson DF, Potosky AL. Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Med Care 2007;45:154-9.
17. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al.Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-61.
18. Hoffman RM, Gilliland FD, Penson DF, Stone SN, Hunt WC, Potosky AL. Cross-sectional and longitudinal comparisons of healthrelated quality of life between patients with prostate carcinoma and matched controls. Cancer 2004;101:2011-9.
19. Dall'era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 2008;112:1650-9.
20. Vickers AJ,Bianco FJ, SerioAM, EasthamJA, Schrag D, Klein EA, et al. The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst 2007;99:1171-7.
21. Australian Bureau of Statistics. Household telephone connections, Queensland, Oct 2003. Catalogue number 8159.3. ABS, 2004.
22. Litwin MS, McGuigan KA. Accuracy of recall in health-related qualityof-life assessment among men treated for prostate cancer. J Clin Oncol 1999;17:2882-8.
23. ColemanMP, Gatta G, Verdecchia A, Esteve J, Sant M, StormH, et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 2003;14(Suppl 5):v128-v149.
24. Donovan J, Mills N, Smith M, Brindle L, Jacoby A, Peters T, et al. Quality improvement report: improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. BMJ 2002;325:766-70.
25. Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol 2009;27:3916-22.
26. Eton DT, Lepore SJ. Prostate cancer and health-related quality of life: a review of the literature. Psychooncology 2002;11:307-26.
27. Penson DF. Quality of life after therapy for localized prostate cancer. Cancer J 2007;13:318-26.
28. Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlen BJ, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347:790-6.
29. Korfage IJ, Essink-Bot ML, Borsboom GJ, Madalinska JB, Kirkels WJ, Habbema JD, et al. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer 2005;116:291-6.
30. Penson DF, Feng Z, Kuniyuki A,McClerran D, Albertsen PC, Deapen D, et al. General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results fromthe prostate cancer outcomes study. J Clin Oncol 2003;21:1147-54.
31. Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000;55:58-61.
32. Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT. Factors predicting recovery of erections after radical prostatectomy. J Urol 2000;164:1929-34.
33. Wilt TJ, Shamliyan TA, Taylor B, MacDonald R, Tacklind J, Rutks I, et al. Comparative effectiveness of therapies for clinically localized prostate cancer. Review number 13 ed. Agency for Healthcare Research and Quality, 2008.
34. Litwin MS, Lubeck DP, Henning JM, Carroll PR. Differences in urologist and patient assessments of health related quality of life inmen with prostate cancer: results of the CaPSURE database. J Urol 1998;159:1988-92.
35. Wei JT, Montie JE. Comparison of patients' and physicians' rating of urinary incontinence following radical prostatectomy. Semin Urol Oncol 2000;18:76-80.
36. Arredondo SA, Downs TM, Lubeck DP, Pasta DJ, Silva SJ, Wallace KL, et al. Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J Urol 2004;172:1830-4.
37. Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004;96:1358-67.
38. Mols F, van de Poll-Franse LV, Vingerhoets AJ, Hendrikx A, Aaronson NK, Houterman S, et al. Long-term quality of life among Dutch prostate cancer survivors: results of a population-based study. Cancer 2006;107:2186-96.
39. Johnson TK, Gilliland FD, Hoffman RM, Deapen D, Penson DF, Stanford JL, et al. Racial/ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. J Clin Oncol 2004;22:4193-201.